PDCD1 and cancer: Numerous studies have demonstrated that the blockage of PD-L1 or PD-1 is one of the most promising approaches for cancer immunotherapy (Zitvogel and Kroemer, 2012; Wu et al., 2018; Salmaninejad et al., 2019).